Crizotinib is an orally available, small molecule ATP-competitive ALK inhibitor that was originally intended as a MET TKI [34] and then quickly redirected towards ALK upon discovery of the role of ALK rearrangements in NSCLC [17]. This evidence concerns the gene ALK and non-small cell lung carcinoma.